Literature DB >> 2937468

Expression of normal myeloid-associated antigens by acute leukemia cells.

P A Dinndorf, R G Andrews, D Benjamin, D Ridgway, L Wolff, I D Bernstein.   

Abstract

Monoclonal antibodies that react with hematopoietic cells and their precursors in a stage and lineage restricted fashion were used in indirect immunofluorescence assays to examine leukemic cells from 105 pediatric age patients. The differentiative states of blasts from 42 patients with acute nonlymphocytic leukemia (ANLL) were defined by these antibodies. When these were compared to their morphologic and histochemical levels of differentiation as defined by the French-American-British (FAB) classification, no direct relationship was found. The reactivity of these antibodies with leukemic cells from 63 patients with acute lymphocytic leukemiA (ALL) was also investigated, and the usefulness of these antibodies in distinguishing leukemias of myeloid from those of lymphoid origin was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2937468

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

Review 1.  Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.

Authors:  Lauren McLaughlin; C Russell Cruz; Catherine M Bollard
Journal:  Ther Adv Hematol       Date:  2015-12

2.  CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.

Authors:  S S Kenderian; M Ruella; O Shestova; M Klichinsky; V Aikawa; J J D Morrissette; J Scholler; D Song; D L Porter; M Carroll; C H June; S Gill
Journal:  Leukemia       Date:  2015-02-27       Impact factor: 11.528

Review 3.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

4.  FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.

Authors:  Kelly J Norsworthy; Chia-Wen Ko; Jee Eun Lee; Jiang Liu; Christy S John; Donna Przepiorka; Ann T Farrell; Richard Pazdur
Journal:  Oncologist       Date:  2018-04-12

5.  Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.

Authors:  Jessica A Pollard; Todd A Alonzo; Michael Loken; Robert B Gerbing; Phoenix A Ho; Irwin D Bernstein; Susana C Raimondi; Betsy Hirsch; Janet Franklin; Roland B Walter; Alan Gamis; Soheil Meshinchi
Journal:  Blood       Date:  2012-02-29       Impact factor: 22.113

6.  Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.

Authors:  Carol O'Hear; Joshua F Heiber; Ingo Schubert; Georg Fey; Terrence L Geiger
Journal:  Haematologica       Date:  2014-12-05       Impact factor: 9.941

7.  Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.

Authors:  Patrice Chevallier; Beatrice Mahe; Richard Garand; Pascaline Talmant; Jean-Luc Harousseau; Jacques Delaunay
Journal:  Int J Hematol       Date:  2008-08-01       Impact factor: 2.490

Review 8.  Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.

Authors:  Daniel G Guy; Geoffrey L Uy
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 9.  Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments.

Authors:  Jeffrey C Bryan; Elias J Jabbour
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923

10.  P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.

Authors:  Ruoping Tang; Simy Cohen; Jean-Yves Perrot; Anne-Marie Faussat; Claudia Zuany-Amorim; Zora Marjanovic; Hamid Morjani; Fanny Fava; Elise Corre; Ollivier Legrand; Jean-Pierre Marie
Journal:  BMC Cancer       Date:  2009-06-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.